A 26-week, Multicentre, Open-labelled, Non-randomised, Non-interventional, Observational, Safety Study of NovoNorm (Repaglinide) and Insulin Analogue Combination Therapy in Type 2 Diabetes in Korea.
Phase of Trial: Phase IV
Latest Information Update: 09 Oct 2014
At a glance
- Drugs Repaglinide (Primary) ; Insulin; Metformin; Thiazolidinediones
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 10 Jun 2017 Biomarkers information updated
- 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Sep 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.